Caseware UK (AP4) 2024.0.164 2024.0.164 2025-02-282025-02-28No description of principal activityfalse2024-02-15true2false 15491498 2024-02-14 15491498 2024-02-15 2025-02-28 15491498 2023-02-15 2024-02-14 15491498 2025-02-28 15491498 c:Director2 2024-02-15 2025-02-28 15491498 c:EntityHasNeverTraded 2024-02-15 2025-02-28 15491498 c:Micro-entities 2024-02-15 2025-02-28 15491498 c:AuditExempt-NoAccountantsReport 2024-02-15 2025-02-28 15491498 c:FullAccounts 2024-02-15 2025-02-28 15491498 c:PrivateLimitedCompanyLtd 2024-02-15 2025-02-28 15491498 d:PoundSterling 2024-02-15 2025-02-28 iso4217:GBP xbrli:pure

Registered number: 15491498










ISM PHARMA HOLDINGS LIMITED








UNAUDITED

FINANCIAL STATEMENTS

INFORMATION FOR FILING WITH THE REGISTRAR

FOR THE PERIOD ENDED 28 FEBRUARY 2025

 
ISM PHARMA HOLDINGS LIMITED
REGISTERED NUMBER: 15491498

STATEMENT OF FINANCIAL POSITION
AS AT 28 FEBRUARY 2025

2025
£


Current assets
2

Net current assets
 
 
2

Total assets less current liabilities
2


Net assets
2



Capital and reserves
2


Notes


General information

ISM Pharma Holdings Limited is a private company limited by share capital, incorporated in England and Wales, registration number 15491498. The registered office is Level 5A, Maple House, 149 Tottenham Court Road, London, W1T 7NF.


Average number of employees

The average monthly number of employees, including directors, during the period was 2.


Directors' confirmations

The Company was entitled to exemption from audit under section 480 of the Companies Act 2006.

The members have not required the Company to obtain an audit for the period in question in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared in accordance with the provisions applicable to entities subject to the micro-entities' regime.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf on 4 November 2025.




Ranjit Singh Marok
Director

Page 1